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Abstract
Comprehensive metabolite profiling captures many highly heritable traits, including amino acid levels, which are potentially
sensitive biomarkers for disease pathogenesis. To better understand the contribution of genetic variation to amino acid levels,
we performed single variant and gene-based tests of association between nine serum amino acids (alanine, glutamine, glycine,
histidine, isoleucine, leucine, phenylalanine, tyrosine, and valine) and 16.6 million genotyped and imputed variants in 8545 non-
diabetic Finnish men from the METabolic Syndrome In Men (METSIM) study with replication in Northern Finland Birth Cohort
(NFBC1966). We identified five novel loci associated with amino acid levels (P ¼ < 5108): LOC157273/PPP1R3B with glycine
(rs9987289, P ¼ 2.31026); ZFHX3 (chr16:73326579, minor allele frequency (MAF) ¼ 0.42%, P ¼ 3.6109), LIPC (rs10468017, P ¼
1.5108), and WWOX (rs9937914, P ¼ 3.8108) with alanine; and TRIB1 with tyrosine (rs28601761, P¼ 8109). Gene-based tests
identified two novel genes harboring missense variants of MAF <1% that show aggregate association with amino acid levels:
PYCR1 with glycine (Pgene¼ 1.5106) and BCAT2 with valine (Pgene¼ 7.4107); neither gene was implicated by single variant
association tests. These findings are among the first applications of gene-based tests to identify new loci for amino acid levels. In
addition to the seven novel gene associations, we identified five independent signals at established amino acid loci, including
two rare variant signals at GLDC (rs138640017, MAF=0.95%, Pconditional¼ 5.81040) with glycine levels and HAL (rs141635447, MAF
¼ 0.46%, Pconditional¼ 9.41011) with histidine levels. Examination of all single variant association results in our data revealed a
strong inverse relationship between effect size and MAF (Ptrend<0.001). These novel signals provide further insight into the
molecular mechanisms of amino acid metabolism and potentially, their perturbations in disease.
Introduction
Amino acid levels are highly heritable biomarkers of human dis-
ease (1) that have been implicated in a range of clinical syn-
dromes including type 2 diabetes/insulin resistance (2–4), liver
disease (5) and Alzheimer’s disease (6). Previous studies have
together identified>200 common variant signals associated
with amino acid levels (7–20). However, the contribution of
genetic variation to amino acid level trait variance, and the role
of rare genetic variation in particular, is not fully understood.
One method of assessing rare variant associations is through
aggregation of multiple rare variants into a single test (21). One
such approach groups rare, protein-altering variants into one
test for association for each gene (21). This method has been
used successfully to identify gene-based associations with HAL
for histidine levels and with PAH for phenylalanine levels (17).
Notably, this result occurred in the absence of any single variant
reaching genome-wide significance in either HAL or PAH, high-
lighting the importance of gene-based tests in identifying novel
genetic loci for complex traits.
In this study, we performed genome-wide single-variant and
gene-based association analysis in 8545 non-diabetic Finnish
men from the METabolic Syndrome In Men (METSIM) study to
identify genetic associations with serum amino acid levels. We
identified seven novel amino acid loci—five from single-variant
tests [of which two signals replicated in the Northern Finnish
Birth Cohort 1966 (NFBC1966) dataset] and two from gene-based
associations. We also performed analyses conditioned on all
previously known amino acid genome-wide association studies
(GWAS) signals and identified five additional novel and
independent signals in known amino acid loci, of which three
replicated in the NFBC1966 data. In total, we identified five novel
and replicated loci-amino acid associations, and two novel
gene-based associations. These results help clarify the role of
the specific variants and genes in amino acid homeostasis.
Results
GWAS for nine amino acids levels
To identify genetic variants associated with the nine amino acid
traits measured in the METSIM study (alanine, glutamine, glycine,
histidine, isoleucine, leucine, phenylalanine, tyrosine and valine;
see Supplementary Material, Figs S1–S3 and Supplementary
Material, Table S1), we analyzed 16.6M genotyped and imputed
variants in 8545 non-diabetic Finnish men of mean age 57 years
and mean BMI 27 kg/m2 (see Supplementary Material, Table S1).
We identified 2428 unique variants associated with at least one
amino acid trait (P< 5 108), and a total of 2580 variant-trait associ-
ations (see Supplementary Material, Table S2 and Figs S4 and S5). Of
the 2580 variant-trait associations, the majority were with glycine
(1403 variants), followed by tyrosine (560), glutamine (164), alanine
(95), leucine (89), isoleucine (87), phenylalanine (67), valine (62) and
histidine (53). We present a summary of the variants and their dis-
tributions in independent loci in Supplementary Material, Table S3.
We estimated for each amino acid trait the phenotypic varia-
tion that genetic variants explained from 10.4% (histidine) to 28.5%
(glycine) of variation (see Supplementary Material, Table S4).
Restricting analysis to genome-wide significant variant-trait asso-
ciations (P< 5 108, see Supplementary Material, Table S2), the
proportion of phenotypic variation explained by significantly
associated variants ranged from 1.3% (leucine) to 18.3% (glycine)
(see Supplementary Material, Table S4).
We attempted to validate genotypes at three rare imputed
trait-associated variants with MAF< 0.5% (see Supplementary
Material, Table S5). We confirmed two variants with no discor-
dance between imputed and sequenced genotypes: rs141635447
(0/74 discordant) and chr16: 73326579 (0/67). Variant chr3:
125173967 showed a discordance rate of 39% (24/61), and was
thus removed from subsequent analyses.
Single-variant analysis identifies novel associations at
LOC157273/PPP1R3B, WWOX, LIPC, TRIB1 and ZFHX3
Genome-wide single-variant analyses identified five novel
amino acid-associated loci at least 1 Mb away from the nearest
known GWAS variant (see Table 1 and Supplementary Material,
Fig. S6A–E). Of the five novel loci (see Table 1), two were located
in the introns of LOC157273 (near PPP1R3B) and WWOX. At the
LOC157273/PPP1R3B locus, intronic variant rs9987289-A was
associated with decreased glycine levels (MAF¼ 17.0%, b ¼ 0.22,
P¼ 2.3 1026, Supplementary Material, Fig. S6A). This variant
was replicated in the NFBC1966 cohort (b ¼ 0.15, P¼ 7.3 104,
see Table 1), and was associated with the risk of type 2 diabetes
[odds Ratio (OR) ¼ 1.05, P ¼ 0.02] and liver disease (OR¼ 1.33,
P¼ 4.7 1018, see Supplementary Material, Table S6). Within the
WWOX region, intronic variant rs9937914-G was associated with
increased alanine levels (MAF¼ 1.47%, b¼ 0.36, P¼ 3.8 108,
Supplementary Material, Fig. S6B).
We identified two additional novel loci in regions previously
highlighted by GWAS: first, in the region upstream of LIPC, a gene
implicated in numerous lipid traits including high-density lipopro-
tein cholesterol (HDL-C) (22), phospholipids (20), and the ratio of
isoleucine and serum total cholesterol (serum-c) (10), rs10468017-T
was associated with increased alanine levels (MAF¼ 33.2%,
b¼ 0.09, P¼ 1.5 108, Supplementary Material, Fig. S6C), and is in
strong linkage disequilibrium (LD) with rs1532085 (LD r2 ¼ 0.66), a
LIPC GWAS locus for HDL (23) and ratio of isoleucine and serum-c
(10). Its association with increased alanine levels was confirmed
in the NFBC1966 cohort (b¼ 0.08, P¼ 7.7 103, see Table 1).
Second, rs28601761-G, for which we report an association with de-
creased tyrosine levels (MAF¼ 42.2%, b ¼ 0.09, P¼ 8.8 109,
Supplementary Material, Fig. S6D), is in strong LD with rs2954029
(LD r2 ¼ 0.71), a TRIB1 GWAS variant for low-density lipoprotein
cholesterol (LDL-C), triglycerides, and HDL-C levels (23,24).
At the remaining novel locus, rare variant 16: 73326579 was
associated with increased alanine levels (MAF¼ 0.42%, b¼ 0.76,
P¼ 3.6 109). The variant 16: 73326579 is located within 300 kb
of both HCCAT5 and ZFHX3, but is not in strong LD (LD r2 < 0.60)
with any coding variant observed in the GoT2D study (see
Supplementary Material, Fig. S6E). We computed P values (PACT)
for the novel variants after correcting for the nine correlated
amino acid traits (25). All of these five novel variants remained
genome-wide significantly associated even after correcting for
the nine amino acid traits (PACT< 5.0108).
Conditional analyses identify independent signals at
five known amino acid loci: GLDC, HAL, ALDH1L1,
ADAMTS3 and GCSH
We curated 1519 unique known amino acid-associated variants,
and then used them as covariates in the genome-wide conditional
analyses (see Supplementary Material, Table S7, Materials and
Methods). After conditional analyses, we observed 227 unique
variant-trait associations (Pconditional < 5 108) (see
Supplementary Material, Table S8), whose distributions in genes
are presented in Supplementary Material, Table S3. Among these,
we identified five novel signals at established amino acid loci dis-
tinct from the previously published GWAS variants (see Table 1):
GLDC p.Q996H, associated with increased glycine (rs138640017-G,
MAF¼ 0.95%, b¼ 1.35, Pconditional ¼ 5.8 1040); HAL p.G283V, asso-
ciated with increased histidine levels (rs141635447-A,
MAF¼ 0.46%, b¼ 0.85, Pconditional ¼ 9.4 1011); rs6564825-G, in an
intron of PKD1L2 and 38 kb downstream of GCSH, was associated
with increased glycine levels (MAF¼ 11.7%, b¼ 0.17, Pconditional ¼
2.0 1010) and nominally but not coincidently associated with ex-
pression level of PKD1L2 (see Supplementary Material, Table S9);
rs190671241-G, an intergenic variant near ADAMTS3, associated
with increased phenylalanine levels (MAF¼ 1.70%, b¼ 0.36,
Pconditional ¼ 2.2 109); and rs112981908-G, an intronic variant of
the ALDH1L1 gene associated with decreased glycine levels
(MAF¼ 11.9%, b ¼ 0.14, Pconditional ¼ 3.1 1010). At each locus, we
observed low pairwise LD (LD r2 < 0.10) between the novel variant
identified in the METSIM data and the previously published GWAS
variant(s). Notably, of the five novel signals at established amino
acid loci, three replicated in the NFBC1966 data: GLDC p.Q996H, as-
sociated with increased glycine (rs138640017-G, b¼ 0.94,
P¼ 2.7 1010); HAL p.G283V, associated with increased histidine
levels (rs141635447-A, b¼ 1.04, P¼ 1.7 105); and ADAMTS3 up-
stream variant rs190671241-G, associated with increased phenyl-
alanine levels (b¼ 0.39, P¼ 1.6 104). Functional work is
necessary to determine whether the novel signals represent addi-
tional functional variants in genes known to play a role in amino
acid metabolism (e.g. GLDC and HAL), or whether they point to
novel mechanisms.
Single-variant associations exhibit an inverse
relationship between allele frequency and effect size
To visualize the relationship between allele frequency and
effect size of amino acid-associated variants, we plotted the ab-
solute value of effect size estimates versus MAF for all loci asso-
ciated with amino acid traits in the METSIM study (P< 5 108)
(see Table 1) and fitted a fractional polynomial spline to the
data (see Fig. 1). These results demonstrated a strong, inverse
relationship between MAF and effect size (Ptrend < 0.001),
consistent with past findings for other traits [e.g. (26)]. This
relationship is largely driven by variants with MAF< 5%, five of
which were newly identified in this study.
Variant associations with amino acid ratios
Prior studies found more genome-wide significant variant associ-
ations with amino acid ratios as compared with amino acid traits
alone (8,12). We identified 15 220 significant variant-ratio associa-
tions (3822 unique variants) from unconditional analyses of the
36 possible ratios among the nine amino acids measured in the
METSIM study. These results are presented in Supplementary
Material, Table S10 as a reference for other investigators.
Gene-based tests identify novel gene associations with
BCAT2 and PYCR1
To determine the joint contribution of the protein-truncating
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































performed gene-based tests (see Supplementary Material, Table
S11 and Fig. S7) and applied a significance threshold based on
the number of genes tested (20 000). Given the high correlation
among amino acid traits levels (see Supplementary Material,
Fig. S2), we did not correct for the number of amino acid
traits as a Bonferroni-corrected significance threshold would be
overly strict. We identified six gene-trait associations
(Pgene< 2.5 106), including four genes previously identified
through single-variant association tests: ALDH1L1 (8) and GLDC
(16) associated with glycine levels, HAL with histidine levels
(16) (see Supplementary Material, Table S12), and DHODH
(previously associated with alanine-to-tyrosine ratio) with
alanine levels, as well as two novel associations between PYCR1
and glycine levels (Pgene ¼ 1.5 106), and BCAT2 and valine
levels (Pgene ¼ 7.4 107, see Table 2).
No missense variants within either PYCR1 or BCAT2 achieved
genome-wide significance with any amino acid trait in the sin-
gle-variant association tests, highlighting the utility of gene-
based test in novel gene discovery (see Table 2). Despite only
suggestive association evidence, the effect of these variants on
amino acid trait variance was considerable (the range of abso-
lute b: 0.36–1.02): the carriers of the two missense variants
within the gene PCYR1 exhibited lower mean glycine levels,
while the carriers of the three variants within the BCAT2 gene
showed higher mean valine levels, suggesting altering their
protein sequences would affect the serum glycine and valine
levels, respectively (see Fig. 2).
Discussion
Amino acids are highly heritable traits whose levels have been
implicated in the pathogenesis of human complex diseases
such as type 2 diabetes (2–4,27,28) and Alzheimer’s disease (6).
Here, we leveraged dense, experimentally determined and im-
puted genotypes and report seven novel amino acid associa-
tions in the METSIM study that replicated in NFBC1966. Of these
associations, two were identified from single-variant testing in
the METSIM study and replicated in the NFBC1966 data, and two
other loci were identified from gene-based analyses in the
METSIM study alone. One of these newly identified variants
from single-variant analyses, LOC157273/PPP1R3B variant
rs9987289-A, also confers increased risk of type 2 diabetes and
liver disease. In addition, we fine-mapped known amino acid
loci and identified and replicated distinct association signals at
three of these loci. Phenotypic variance explained for these nine
amino acids by known and novel associations ranged from
10.4% for histidine levels to 28.5% for glycine levels in our data.
These results further elucidate the potential mechanisms
through which amino acid levels are perturbed, and their poten-
tial relationship to disease.
Novel loci highlight a potential role for genes implicated
in lipid metabolism and human diseases
Of the five novel amino acid loci highlighted in this study
through single-variant analyses, four have previously been im-
plicated in lipid metabolism. First, the rs9987289-A signal near
LOC157273/PPP1R3B, for which we report an association with de-
creased glycine levels, has previously been associated with de-
creased HDL-C, LDL-C and total cholesterol levels (23), as well as
increased PPP1R3B expression levels in human liver tissue (23).
In addition, overexpression of Ppp1r3b led to a significant de-
crease in HDL-C and total cholesterol in a mouse model (23).
This variant is also associated with increased risk of type 2 dia-
betes (29) and liver disease (30). Second, the rs10468017-T signal
upstream of LIPC associated with increased alanine levels has
previously been associated with increased HDL-C (22), altered
levels of several circulating phospholipids (20), and the ratio of
isoleucine and serum-c (10). Third, the signal near TRIB1 associ-
ated with decreased tyrosine levels has previously been associ-
ated with decreased total cholesterol, LDL-C and triglyceride
levels (23). Finally, we reported an intronic WWOX variant,
rs9937914-G, associated with increased alanine levels, and hu-
man carriers of predicted loss-of-function variants in WWOX
were reported to have lower HDL-C (31) levels; in addition, mice
lacking Wwox exhibit decreased fasting cholesterol, triglyceride
and glucose levels (32). These variant associations may repre-
sent a secondary effect of altered lipid levels on amino acid me-
tabolism, as previously demonstrated in the setting of obesity
(33) and insulin resistance (2). Further work will be required to
determine the mechanisms through which these lipid-related
loci affect amino acid levels and human complex diseases.
Gene-based tests highlight two novel loci not identified
from single-variant testing
PYCR1, which we identified as a gene implicated in glycine
levels, encodes a mitochondrial protein involved in biosynthesis
of proline and generation of oxidative potential through
NADPþproduction (34). PYCR1 was recently identified as the ge-
netic cause of autosomal recessive cutis laxa type 2, highlighting
the importance of normal PYCR1 function in neurodevelopment
(35). Functional studies of fibroblasts from affected individuals
found increased sensitivity to oxidative stress (36). As redox
reactions are critical to amino acid biosynthesis (37), our finding
Figure 1. Relationship between minor allele frequency and estimated beta
coefficient (b) for loci associated with amino acid levels in the METSIM data.
All novel amino acid loci (triangles in pink) are highlighted, in addition to novel
signals at known amino acid loci (squares in green) identified through analyses
conditioned on all known amino acid GWAS variants. The known amino acid
signals are represented with blue circles. The dashed gray line represents a
fractional polynomial spline fitted to the data points (P<0.001). b, on the y-axis,
is the absolute value of the estimated regression coefficient for a given variant-
trait association.
that PYCR1 missense variants result in decreased glycine levels
may suggest reduced oxidative potential in vivo.
We also identified an association between BCAT2 variants
and valine levels through gene-based testing. BCAT2 encodes a
mitochondrial enzyme responsible for the first steps in the
breakdown of branched chain amino acids (isoleucine, leucine
and valine) (37); thus the relationship of BCAT2 with valine lev-
els is clear. Prior literature reports that the deletion of exon 2 in
the mouse homologue of BCAT2 resulted in a phenotype similar
to Maple Syrup Urine Disease (38), an autosomal recessive hu-
man inborn error of metabolism characterized by high levels of
branched chain amino acids and resulting neurologic symp-
toms due to the inability to catabolize dietary branched chain
amino acids. A human case study of an adult male with mild
neurologic symptoms (headaches and mild memory loss) has
been reported similar findings, with R170Q and E264K missense
variants in BCAT2 resulting in higher-than-expected levels of
leucine, isoleucine and valine (39). Therefore, our finding of
BCAT2 missense variants resulting in increased valine levels is
supported by prior literature.
Limitations
Some limitations of this study should be considered. First, our
analyses were limited by statistical power secondary to sample
size. This was likely one of the contributing factors to our lack
of replication of single variant signals in the NFBC1966 data, as
the available NFBC1966 replication sample size was modest.
Future meta-analyses of amino acid associations are likely to
clarify true signals from false positives. Second, our discovery
and replication populations of Finnish men (and women for the
replication study) limit the generalizability of our findings.
However, this study design also provided the genetic homoge-
neity needed to identify Finnish-ancestry-specific rare variant
associations with amino acid traits. Third, our results infer
association between genetic markers and amino acid traits;
however, elucidating the causal mechanism through which
these variants affect amino acid levels will require further func-
tional work.
Summary
These GWAS of nine amino acid traits in 8545 participants of
the METSIM study identified five novel single-variant associa-
tions, including variant-trait associations near LOC157273/
PPP1R3B, WWOX, TRIB1, LIPC and ZFHX3, of which two were rep-
licated in the NFBC1966 cohort and one (LOC157273/PPP1R3B)
was also associated with the risk of type 2 diabetes and liver dis-
ease. In addition, we identified two novel gene-based signals
driven by two and three potentially functional missense vari-
ants at PYCR1 and BCAT2, respectively. In BCAT2, we validated
the association of one rare missense variant in the NFBC1966
study. Our use of a dense reference panel yielded 16.6M geno-
typed and imputed variants, allowing for high-resolution analy-
ses and fine mapping of independent genetic signals at GLDC,
GCSH, ALDH1L1, ADAMTS3 and HAL; of which the signals at
GLDC, HAL and ADAMTS3 were replicated in the NFBC1966 data.
Further work is needed to determine which of the variants iden-
tified in this study may affect gene function and the precise
roles of the identified genes in amino acid metabolism. These
analyses provide further insight into the molecular mecha-
nisms of amino acid metabolism, and, given the importance of
amino acid level perturbation in the pathogenesis of numerous




Of the 10 197 participants in the METSIM study, we analyzed the
subset of 8545 non-diabetic men of mean age 57.3 6 7.1 years
Table 2. Novel gene-based associations with amino acid traits









Novel gene-based associations with amino acid traits
Gly PYCR1 1.5 106 — — —
rs3744807 17: 79890818 G297R 0.13 (T) 8532/22/0 1.02 1.62  106 0.01 1.2 0.23
rs142225075 17: 79893020 L108V 0.10 (C) 8528/17/0 0.42 0.08 0.09 0.5 0.30
Val BCAT2 7.4  107 — — —
rs199999090 19: 49299714 R331C 0.18(A) 8515/30/0 0.63 5.36  104 — — —
rs117048185 19: 49309776 Q60E 0.59 (C) 8445/100/0 0.36 4.12  104 0.71 0.6 0.0003
rs201148940 19: 49309937 H6R 0.02 (C) 8542/3/0 0.42 0.46 Monomorphic
Novel gene-based associations with amino acid traits, established association with amino acid ratios
Ala DHODHb 1.36  107 — — —
rs201970636 16: 72055088 A195T 0.41 (A) 8475/70/0 0.64 1.94  107 0.76 0.3 0.047
rs201202896 16: 72055187 E228K 0.01 (A) 8544/1/0 0.80 0.42 — — —
rs199626701 16: 72057113 A290V 0.01 (T) 8544/1/0 1.13 0.26 — — —
rs200181357 16: 72057134 R297H 0.01 (A) 8543/2/0 0.22 0.76 Monomorphic
rs192923495 16: 72057193 R317W 0.09 (T) 8529/16/0 0.26 0.30 0.32 0.0 0.92
Abbreviations: b, estimated regression coefficient for the minor allele; Chr: Pos, variant chromosome and position based on hg19 build; MAF(%), minor allele frequency
(in percent) with minor allele in parentheses.
Amino acid abbreviations: Ala, alanine; Gly, glycine; His, histidine; Val, valine.
aPosition based on hg19 build.
bSNPs in DHODH previously associated with alanine-to-tyrosine ratio by Kettunen et al. (8).
and BMI 27.0 6 4.0 kg/m2 with NMR amino acid trait measure-
ments (see Supplementary Material, Table S1). Institutional re-
view boards at the University of Kuopio and Kuopio University
approved the METSIM study. Written informed consent was
obtained from each participant.
Amino acid trait measurement
Blood samples from METSIM participants were obtained and
stored in liquid nitrogen until measurement by NMR, as previ-
ously described (40). In brief, fasting serum samples collected at
enrollment were stored at80C and thawed overnight in a refrig-
erator before sample preparation. A high-throughput serum NMR
metabolomics platform was then used to quantify the levels of in-
dividual metabolites using a low-molecular weight metabolite
data window (1H NMR spectra) used to identify amino acids (41).
We then used iterative lineshape fitting with known chemical
shifts to identify and quantify each specific metabolite (42).
We measured nine amino acid levels by NMR spectroscopy:
alanine, glutamine, glycine, histidine, isoleucine, leucine, phe-
nylalanine, tyrosine and valine (see Supplementary Material,
Table S1). Visualization of the Pearson pairwise correlation ma-
trix between the nine measured amino acid traits was gener-
ated using the corrplot package (https://cran.r-project.org/web/
packages/corrplot/index.html; date last accessed March 5, 2018)
within R (see Supplementary Material, Fig. S2).
Genotyping and imputation
METSIM participant samples were genotyped on the Human
OmniExpresss-12v1_C BeadChip (OmniExpress) and Infinium
HumanExome-12 v1.0 BeadChip (Exome Chip) platforms.
Quality controls included sample-level controls for sex and re-
latedness confirmation, sample duplication, and detection of
sample genetic ancestry outliers using principal component
analysis. Based on these quality control measures, we removed
14 samples with sex chromosome anomalies, 18 with evidence
of participant duplication, 12 population outliers and 9 samples
with non-Mendelian inheritance inconsistencies. In addition,
we removed one individual from each of seven monozygotic
twin pairs.
We filtered variants with low mapping quality of probes to ge-
nome build GRCh37, low genotype completeness (<95% and<98%
for the OmniExpress and ExomeChip, respectively), or Hardy-
Weinberg equilibrium P< 106.
We phased OmniExpress variants passing quality control
with SHAPEIT v2 (43) and imputed them using minimac v2 (44).
For imputation, we used a reference panel of 20.9M variants
from the GoT2D study (including SNVs, indels and large dele-
tions) based on the whole genome sequence of 2874 Europeans,
including 1004 Finnish individuals—the largest panel of Finnish
genomes available (45). Following imputation, variants directly
genotyped on the ExomeChip were added. In cases of common
markers between imputed and genotyped variants, we used the
directly genotyped call from the ExomeChip. The distribution of
imputation quality and MAF for each imputed variants are pre-
sented in Supplementary Material, Figure S3. We carried forward
16 607 533 variants with high imputation quality (i.e. minimac
RSQ 0.3) for further single-variant association testing.
Single-variant analyses
We performed single-variant association tests on imputed geno-
type dosages for all variants with a minor allele count 3.
Association tests assumed an additive genotype model and ac-
counted for cryptic relatedness among the Finnish population
using the EMMAX linear mixed model approach (46), as imple-
mented in EPACTS (http://genome.sph.umich.edu/wiki/EPACTS;
date last accessed March 5, 2018). We adjusted amino acid traits
for age, age2 and BMI, and then inverse normalized the residuals.
We applied normalization of trait levels to control for type-I error
caused by skewed distributions, although this normalization
Figure 2. Plots show the trait values of rare variant carriers relative to the distribution of amino acid levels in all individuals. The tables in the right panel show
gene-based tests of association with amino acid levels for genes PYCR1 and BCAT2. Histograms show the distribution of the inverse normalized residuals of the trait
across all participants for the gene-based test of association at (A) PYCR1 with glycine levels and (B) BCAT2 with valine. The dashed gray line represents the mean
inverse normalized residual of trait level for all individuals. The solid black line in each row represents the mean trait level for carriers of each variant. Triangles
represent rare variant carriers. The locations of triangles relative to the distribution across all participants indicate the trait levels of rare variant carriers. No
individuals were homozygous for the minor allele of any of the listed variants.
may reduce power to discover associated variants. We created
association plots for the novel variants using LocusZoom (http://
locuszoom.sph.umich.edu/locuszoom/; date last accessed March
5, 2018). In addition, we computed P-values (PACT) for the
novel variants after correcting for the nine correlated amino acid
traits (25). We used a conventional significance threshold of
P< 5 108 in single-variant association testing.
Replication in the Northern Finnish Birth Cohort
The associations in the novel regions were replicated in silico in the
Northern part of Finland: The 1966 cohort (the ‘Northern Finnish
Birth Cohort’, or NFBC1966) (47). NFBC1966 is a prospective follow-
up study of children from the two northernmost provinces of
Finland born in 1966. All individuals still living in northern Finland
or the Helsinki area (n¼ 8463) were contacted and invited for clini-
cal examination. A total of 6007 participants attended the clinical
examination at the participants’ age of 31 years. Among them,
5402 samples were genotyped on Illumina HumanCNV370DUO
Analysis BeadChip (48), and were then imputed to the Haplotype
Reference Consortium (HRC) reference (49) and 1000 Genomes
Project Phase 3 (50) on the Michigan Imputation Server (https://
imputationserver.sph.umich.edu/index.html; date last accessed
March 5, 2018). The association for the novel region variants and
rare variants were looked up in 2591 samples. Given our focused
hypothesis, we set a threshold for significance in replication as
P0.05.
Associations of novel amino acid SNVs with end-organ
phenotypes
We investigated the association of the novel amino acid regions
variants with the risk of type 2 diabetes, Alzheimer’s diseases and
liver disease. For type 2 diabetes, we used publically available data
in large-scale Europeans (N¼ 159 208) from the DIAGRAM consor-
tium (http://www.diagram-consortium.org; date last accessed
March 5, 2018) (29). For Alzheimer’s disease, we examined associa-
tions in the ADGC consortium (N¼ 54 162) (51). Finally, for liver
disease, we used association summary statistics data the GOLD
consortium (N¼ 7176) (30). We used proxy single-nucleotide poly-
morphisms (SNPs) tightly linking with the novel variant if our vari-
ant was not available.
Analysis of amino acid trait variance
We estimated the phenotypic variance explained by genetic
variants for inverse normalized amino acid traits as described
previously through GCTA v1.26 (see Supplementary Material,
Fig. S1) (52). We removed 1153 close relatives through kinship
cut-off of 0.0075 in KING 1.4 (53), and then estimated the pheno-
typic variance in 7392 unrelated samples (53). To account for
the effect of population structure, we used the top 10 principal
components as covariates. In brief, we carried out a primary
analysis that consisted of a simultaneous analysis of all 16.6M
variants, and a secondary analysis considering only the 2580
variants determined to be genome-wide significant for at least
one amino acid trait (see Supplementary Material, Table S2).
Validation of imputed rare variants
We used TaqMan SNP genotyping (Thermo Fisher Scientific)
or Sanger sequencing to validate genotypes at three trait-
associated (P< 5 108) and rare imputed variants (MAF< 0.5%)
(see Supplementary Material, Table S5). We examined all
individuals predicted (on the basis of imputation) to be hetero-
zygous carriers at any of the three sites, as well as additional
non-carriers.
Genome-wide conditional analyses
To identify additional independent genetic signals for amino acid
traits at known GWAS loci, we conducted a comprehensive
genome-wide conditional association analysis. We curated a data-
base of prior published studies of genetic associations with amino
acid and related traits to identify distinct variant associations in
conditional analyses. To identify published studies, we screened a
GWAS catalogue (http://www.ebi.ac.uk/gwas/; date last accessed
March 5, 2018), used SNIPPER (https://csg.sph.umich.edu/boehnke/
snipper/; date last accessed March 5, 2018) to query publicly avail-
able databases for published variants and loci, and performed liter-
ature review using PubMed (https://www.ncbi.nlm.nih.gov/
pubmed/; date last accessed March 5, 2018) and Google Scholar
(https://scholar.google.com; date last accessed March 5, 2018). We
focused on proteinogenic amino acid and related traits (e.g. citrate)
in European populations (see Supplementary Material, Table S7).
The curated list contained 2615 variants (of which 1519 were
unique, with several variants having multiple trait associations)
spanning>100 loci from 14 studies (see Supplementary
Material, Table S7). These associated variants were then filtered
for pairwise LD (r2 > 0.95) to 408 variants (see Supplementary
Material, Table S7). For the 2580 amino acid associated variants
identified in discovery analyses (see Supplementary Material,
Table S2), we performed a secondary analysis conditioning on
the LD-pruned list of 408 independent genetic variants. A vari-
ant with P-value< 5 108 was considered to be a novel second-
ary signal within known amino acid traits loci after
conditioning on these 408 independent genetic variants.
Amino acid ratio tests of association
Prior investigations of genetic associations with amino acid trait
variation have reported extensive findings with amino acid
ratios (8,12). While amino acid ratios were not the focus of our
investigation, we included discovery analyses with 36 amino
acid ratios listed in Supplementary Material, Table S10.
Gene-based tests of association
We performed gene-based tests of association using SKAT-O
(21) with EMMAX (46) to determine the joint contribution of
protein-truncating (i.e. nonsense, frameshift and essential
splice variants) and missense variants with MAF< 1% on amino
acid traits, as described in our previous study (54). For these
analyses, we included only coding variants directly genotyped
on either the OmniExpress or Exome array. Missing genotype
data (proportion< 2%) were imputed with variant-specific mean
genotype since SKAT-O requires complete data (21). A total of
51 898 protein-truncating or missense variants in 13 996 genes
met these criteria (see Supplementary Material, Table S11 for a
summary of variant distributions within genes). We considered
a gene-based result exome-wide significant at a P-value thresh-
old of 2.5 106 (0.05/20 000) to account for the number of genes
in these gene-based analyses.
Supplementary Material
Supplementary Material is available at HMG online.
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Soininen, P., Sarin, A.-P., Tikkanen, E., O’Reilly, P.F.,
Savolainen, M.J., Kaski, K. et al. (2012) Detailed metabolic and
genetic characterization reveals new associations for 30
known lipid loci. Hum. Mol. Genet., 21, 1444–1455.
11. Rhee, E.P., Ho, J.E., Chen, M.-H., Shen, D., Cheng, S., Larson,
M.G., Ghorbani, A., Shi, X., Helenius, I.T., O’Donnell, C.J. et al.
(2013) A genome-wide association study of the human metab-
olome in a community-based cohort. Cell Metab., 18, 130–143.
12. Shin, S.-Y., Fauman, E.B., Petersen, A.-K., Krumsiek, J.,
Santos, R., Huang, J., Arnold, M., Erte, I., Forgetta, V., Yang,
T.-P. et al. (2014) An atlas of genetic influences on human
blood metabolites. Nat. Genet., 46, 543–550.
13. Demirkan, A., Henneman, P., Verhoeven, A., Dharuri, H.,
Amin, N., van Klinken, J.B., Karssen, L.C., de Vries, B.,
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L.-P., Pirinen, M. et al. (2016) Genome-wide study for circulat-
ing metabolites identifies 62 loci and reveals novel systemic
effects of LPA. Nat. Commun., 7, 11122.
17. Rhee, E.P., Yang, Q., Yu, B., Liu, X., Cheng, S., Deik, A., Pierce,
K.A., Bullock, K., Ho, J.E., Levy, D. et al. (2016) An exome array
study of the plasma metabolome. Nat. Commun., 7, 12360.
18. Yet, I., Menni, C., Shin, S.-Y., Mangino, M., Soranzo, N., Adamski,
J., Suhre, K., Spector, T.D., Kastenmüller, G. and Bell, J.T. (2016)
Genetic Influences on Metabolite Levels: a Comparison across
Metabolomic Platforms. PLoS One, 11, e0153672.
19. Long, T., Hicks, M., Yu, H.-C., Biggs, W.H., Kirkness, E.F.,
Menni, C., Zierer, J., Small, K.S., Mangino, M., Messier, H. et al.
(2017) Whole-genome sequencing identifies common-to-rare
variants associated with human blood metabolites. Nat.
Genet., 49, 568–578.
20. Demirkan, A., van Duijn, C.M., Ugocsai, P., Isaacs, A.,
Pramstaller, P.P., Liebisch, G., Wilson, J.F., Johansson, A.,
Rudan, I., Aulchenko, Y.S. et al. (2012) Genome-wide associa-
tion study identifies novel loci associated with circulating
phospho- and sphingolipid concentrations. PLoS Genet., 8,
e1002490–e1002414.
21. Lee, S., Abecasis, G.R., Boehnke, M. and Lin, X. (2014)
Rare-variant association analysis: study designs and statis-
tical tests. Am. J. Hum. Genet., 95, 5–23.
22. Kathiresan, S., Willer, C.J., Peloso, G.M., Demissie, S.,
Musunuru, K., Schadt, E.E., Kaplan, L., Bennett, D., Li, Y.,
Tanaka, T. et al. (2009) Common variants at 30 loci contribute
to polygenic dyslipidemia. Nat. Genet., 41, 56–65.
23. Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson,
A.C., Stylianou, I.M., Koseki, M., Pirruccello, J.P., Ripatti, S.,
Chasman, D.I., Willer, C.J. et al. (2010) Biological, clinical and
population relevance of 95 loci for blood lipids. Nature, 466,
707–713.
24. Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M.,
Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., Buchkovich,
M.L., Mora, S. et al. (2013) Discovery and refinement of loci as-
sociated with lipid levels. Nat. Genet., 45, 1274–1283.
25. Conneely, K.N. and Boehnke, M. (2007) So many corre-
lated tests, so little time! Rapid adjustment of P values
for multiple correlated tests. Am. J. Hum. Genet., 81,
1158–1168.
26. Lange, L.A., Hu, Y., Zhang, H., Xue, C., Schmidt, E.M., Tang,
Z.-Z., Bizon, C., Lange, E.M., Smith, J.D., Turner, E.H. et al.
(2014) Whole-exome sequencing identifies rare and
low-frequency coding variants associated with LDL choles-
terol. Am. J. Hum. Genet., 94, 233–245.
27. McCarty, M.F. and DiNicolantonio, J.J. (2014) The cardiometa-
bolic benefits of glycine: is glycine an ‘antidote’ to dietary
fructose? Open Heart, 1, e000103.
28. Kim, D.S., Jackson, A.U., Li, Y.K., Stringham, H.M., FinMetSeq
Investigators, Kuusisto, J., Kangas, A.J., Soininen, P., Ala-
Korpela, M., Burant, C.F. et al. (2017) Novel association of
TM6SF2 rs58542926 genotype with increased serum tyrosine
levels and decreased apoB-100 particles in Finns. J. Lipid Res.,
58, 1471–1481.
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